Stock market today: Nasdaq closes above 23,000 for first time as tech rebounds
M33 Growth I L.P., M33 Growth I GP LLC and TOI M, LLC, all listed as ten-percent owners of Oncology Institute Inc (NASDAQ:TOI), reported selling 6,700,000 shares of common stock on September 4, 2025. The sales were executed at a price of $3.09, totaling $20,702,999. The transaction comes as TOI shares have shown remarkable strength, posting a 955% return year-to-date according to InvestingPro data, with analyst price targets ranging from $6 to $8.
M33 Growth I L.P. sold 6,018,168 shares directly. Following the transaction, M33 Growth I L.P. directly owns 7,932,389 shares of Oncology Institute.
TOI M, LLC disposed of 681,832 shares. After the transaction, TOI M, LLC indirectly holds 590,892 shares in Oncology Institute.
In other recent news, The Oncology Institute reported its second quarter earnings, which fell short of analyst expectations. Despite this earnings miss, the company experienced strong revenue growth that surpassed forecasts. These recent developments highlight the mixed financial results for the company. The earnings report was significant enough to impact investor sentiment. Analyst firms had projected certain figures, but the earnings did not align with these estimates. The revenue performance, however, was a positive aspect, as it exceeded what analysts had anticipated. This mixed financial outcome is a critical point of interest for investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.